To The Moon
Home
News
TigerAI
Log In
Sign Up
keozmi
+Follow
Posts · 18
Posts · 18
Following · 0
Following · 0
Followers · 0
Followers · 0
keozmi
keozmi
·
2021-07-10
Ok
Sorry, this post has been deleted
看
2.14K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
keozmi
keozmi
·
2021-06-28
Ok
Sorry, this post has been deleted
看
2.12K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
keozmi
keozmi
·
2021-06-17
Ok
Sorry, this post has been deleted
看
1.71K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
keozmi
keozmi
·
2021-06-16
Ok
Sorry, this post has been deleted
看
2.05K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
keozmi
keozmi
·
2021-06-14
Ok
GSK, iTeos to develop cancer drug in up to $2 bln deal
June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to iTeos Therap
GSK, iTeos to develop cancer drug in up to $2 bln deal
看
2.96K
回复
1
点赞
1
编组 21备份 2
Share
Report
keozmi
keozmi
·
2021-06-13
ok
Sorry, this post has been deleted
看
2.62K
回复
1
点赞
1
编组 21备份 2
Share
Report
keozmi
keozmi
·
2021-06-12
Yes
Sorry, this post has been deleted
看
2.58K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
keozmi
keozmi
·
2021-06-09
O
Sorry, this post has been deleted
看
2.21K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
keozmi
keozmi
·
2021-06-08
Ok
Dada surged more than 8% in premarket trading
(June 8) Dada surged more than 8% in premarket trading.Hours ago, Dada Nexus reports Q1 adjusted los
Dada surged more than 8% in premarket trading
看
2.18K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
keozmi
keozmi
·
2021-06-04
Ok
3 Top Robinhood Stocks Wall Street Thinks Will Soar 25% or More
Analysts expect one of them to skyrocket a lot more than 25%.
3 Top Robinhood Stocks Wall Street Thinks Will Soar 25% or More
看
2.48K
回复
Comment
点赞
5
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3578224654391596","uuid":"3578224654391596","gmtCreate":1615130630652,"gmtModify":1615130630652,"name":"keozmi","pinyin":"keozmi","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":1,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":148396774,"gmtCreate":1625926615198,"gmtModify":1703750967105,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/148396774","repostId":"2150370120","repostType":4,"isVote":1,"tweetType":1,"viewCount":2144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127913555,"gmtCreate":1624812802477,"gmtModify":1703845475927,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127913555","repostId":"2146000990","repostType":4,"isVote":1,"tweetType":1,"viewCount":2116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161193954,"gmtCreate":1623908761478,"gmtModify":1703823267956,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161193954","repostId":"2143379379","repostType":4,"isVote":1,"tweetType":1,"viewCount":1707,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160777309,"gmtCreate":1623807953401,"gmtModify":1703820056180,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160777309","repostId":"1179874077","repostType":4,"isVote":1,"tweetType":1,"viewCount":2048,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185737205,"gmtCreate":1623672913207,"gmtModify":1704208281256,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/185737205","repostId":"2143782408","repostType":4,"repost":{"id":"2143782408","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623671890,"share":"https://ttm.financial/m/news/2143782408?lang=&edition=fundamental","pubTime":"2021-06-14 19:58","market":"us","language":"en","title":"GSK, iTeos to develop cancer drug in up to $2 bln deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2143782408","media":"Reuters","summary":"June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to iTeos Therap","content":"<p>June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to <a href=\"https://laohu8.com/S/ITOS\">iTeos Therapeutics</a> Inc to develop and sell a potential cancer treatment together, the companies said on Monday.</p>\n<p>Boston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development and commercial milestones.</p>\n<p>GlaxoSmithKline is under pressure to shore up its drug pipeline after a report that U.S. activist investor Elliott built up a significant stake in the company. The British drugmaker is also preparing to outline plans to split its consumer products business from its drug operations.</p>\n<p>The iTeos deal is to develop EOS-448, a monoclonal antibody using an anti-TIGIT agent which showed promise in early studies.</p>\n<p>Anti-TIGIT treatments are new experimental immunotherapies against certain cancer types. These treatments, including Roche's tiragolumab and Merck & Co's vibostolimab, are designed to deactivate a tumour's ability to evade the immune system.</p>\n<p>EOS-448 is currently being tested in an early-stage study in patients with advanced solid tumors.</p>\n<p>GSK and iTeos plan to start combination studies of EOS-448 with GSK's cancer drug dostarlimab in 2022.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK, iTeos to develop cancer drug in up to $2 bln deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK, iTeos to develop cancer drug in up to $2 bln deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-14 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to <a href=\"https://laohu8.com/S/ITOS\">iTeos Therapeutics</a> Inc to develop and sell a potential cancer treatment together, the companies said on Monday.</p>\n<p>Boston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development and commercial milestones.</p>\n<p>GlaxoSmithKline is under pressure to shore up its drug pipeline after a report that U.S. activist investor Elliott built up a significant stake in the company. The British drugmaker is also preparing to outline plans to split its consumer products business from its drug operations.</p>\n<p>The iTeos deal is to develop EOS-448, a monoclonal antibody using an anti-TIGIT agent which showed promise in early studies.</p>\n<p>Anti-TIGIT treatments are new experimental immunotherapies against certain cancer types. These treatments, including Roche's tiragolumab and Merck & Co's vibostolimab, are designed to deactivate a tumour's ability to evade the immune system.</p>\n<p>EOS-448 is currently being tested in an early-stage study in patients with advanced solid tumors.</p>\n<p>GSK and iTeos plan to start combination studies of EOS-448 with GSK's cancer drug dostarlimab in 2022.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","ITOS":"iTeos Therapeutics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143782408","content_text":"June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to iTeos Therapeutics Inc to develop and sell a potential cancer treatment together, the companies said on Monday.\nBoston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development and commercial milestones.\nGlaxoSmithKline is under pressure to shore up its drug pipeline after a report that U.S. activist investor Elliott built up a significant stake in the company. The British drugmaker is also preparing to outline plans to split its consumer products business from its drug operations.\nThe iTeos deal is to develop EOS-448, a monoclonal antibody using an anti-TIGIT agent which showed promise in early studies.\nAnti-TIGIT treatments are new experimental immunotherapies against certain cancer types. These treatments, including Roche's tiragolumab and Merck & Co's vibostolimab, are designed to deactivate a tumour's ability to evade the immune system.\nEOS-448 is currently being tested in an early-stage study in patients with advanced solid tumors.\nGSK and iTeos plan to start combination studies of EOS-448 with GSK's cancer drug dostarlimab in 2022.","news_type":1,"symbols_score_info":{"GSK":0.9,"ITOS":0.9}},"isVote":1,"tweetType":1,"viewCount":2963,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182674519,"gmtCreate":1623573149132,"gmtModify":1704206474874,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/182674519","repostId":"2143788716","repostType":4,"isVote":1,"tweetType":1,"viewCount":2622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186820225,"gmtCreate":1623485692367,"gmtModify":1704204944566,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186820225","repostId":"1133871419","repostType":4,"isVote":1,"tweetType":1,"viewCount":2578,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":189175877,"gmtCreate":1623249710799,"gmtModify":1704199389981,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/189175877","repostId":"2142600282","repostType":4,"isVote":1,"tweetType":1,"viewCount":2210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117293556,"gmtCreate":1623141716575,"gmtModify":1704196925965,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/117293556","repostId":"1144438912","repostType":4,"repost":{"id":"1144438912","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623140401,"share":"https://ttm.financial/m/news/1144438912?lang=&edition=fundamental","pubTime":"2021-06-08 16:20","market":"us","language":"en","title":"Dada surged more than 8% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1144438912","media":"Tiger Newspress","summary":"(June 8) Dada surged more than 8% in premarket trading.Hours ago, Dada Nexus reports Q1 adjusted los","content":"<p>(June 8) Dada surged more than 8% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/9d774d3b39e0017fac96a0eeb4e0ec75\" tg-width=\"750\" tg-height=\"514\" referrerpolicy=\"no-referrer\"></p><p>Hours ago, Dada Nexus reports Q1 adjusted lossof RMB0.65 per share vs. a loss of RMB1.11 per share in lastyear's quarter.</p><p>Total net revenues rose 52.1% Y/Y to RMB1,672.8 million.</p><p>Non-GAAP loss from operations was RMB648.1 million, compared with RMB205.5 million.</p><p>As of March 31, 2021, the Company had RMB5,485.8 million in cash, cash equivalents, restricted cash and short-term investments.</p><p>Total Gross Merchandise Volume of JDDJ for the twelve months ended March 31, 2021 rose 79% Y/Y to RMB28.1 billion.</p><p>Number of active consumers for the twelve months ended March 31, 2021 rose 67% Y/Y to 46.1M.</p><p><b>Q2 Outlook:</b>Total revenue of RMB1.4B-1.45B (about $219-$226.9M) vs. a consensus of $244.4M.</p><p>“We delivered another solid quarter and expect the strong growth momentum will continue,” said Beck Chen, Chief Financial Officer of Dada. “We expect the pro forma growth of total revenue of the Q2 will be 72% to 78%, adjusting the revenue recognition of last-mile delivery services to net basis in Q2 of 2020 and 2021. We are excited with JDDJ’s strong growth momentum, and are confident that year-over-year growth rate of JDDJ’s revenue will be over 80% in Q2 and will further accelerate in the second half of 2021.”</p><p>The Company also announces $150 million share repurchase plan.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dada surged more than 8% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDada surged more than 8% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-08 16:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 8) Dada surged more than 8% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/9d774d3b39e0017fac96a0eeb4e0ec75\" tg-width=\"750\" tg-height=\"514\" referrerpolicy=\"no-referrer\"></p><p>Hours ago, Dada Nexus reports Q1 adjusted lossof RMB0.65 per share vs. a loss of RMB1.11 per share in lastyear's quarter.</p><p>Total net revenues rose 52.1% Y/Y to RMB1,672.8 million.</p><p>Non-GAAP loss from operations was RMB648.1 million, compared with RMB205.5 million.</p><p>As of March 31, 2021, the Company had RMB5,485.8 million in cash, cash equivalents, restricted cash and short-term investments.</p><p>Total Gross Merchandise Volume of JDDJ for the twelve months ended March 31, 2021 rose 79% Y/Y to RMB28.1 billion.</p><p>Number of active consumers for the twelve months ended March 31, 2021 rose 67% Y/Y to 46.1M.</p><p><b>Q2 Outlook:</b>Total revenue of RMB1.4B-1.45B (about $219-$226.9M) vs. a consensus of $244.4M.</p><p>“We delivered another solid quarter and expect the strong growth momentum will continue,” said Beck Chen, Chief Financial Officer of Dada. “We expect the pro forma growth of total revenue of the Q2 will be 72% to 78%, adjusting the revenue recognition of last-mile delivery services to net basis in Q2 of 2020 and 2021. We are excited with JDDJ’s strong growth momentum, and are confident that year-over-year growth rate of JDDJ’s revenue will be over 80% in Q2 and will further accelerate in the second half of 2021.”</p><p>The Company also announces $150 million share repurchase plan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DADA":"达达集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144438912","content_text":"(June 8) Dada surged more than 8% in premarket trading.Hours ago, Dada Nexus reports Q1 adjusted lossof RMB0.65 per share vs. a loss of RMB1.11 per share in lastyear's quarter.Total net revenues rose 52.1% Y/Y to RMB1,672.8 million.Non-GAAP loss from operations was RMB648.1 million, compared with RMB205.5 million.As of March 31, 2021, the Company had RMB5,485.8 million in cash, cash equivalents, restricted cash and short-term investments.Total Gross Merchandise Volume of JDDJ for the twelve months ended March 31, 2021 rose 79% Y/Y to RMB28.1 billion.Number of active consumers for the twelve months ended March 31, 2021 rose 67% Y/Y to 46.1M.Q2 Outlook:Total revenue of RMB1.4B-1.45B (about $219-$226.9M) vs. a consensus of $244.4M.“We delivered another solid quarter and expect the strong growth momentum will continue,” said Beck Chen, Chief Financial Officer of Dada. “We expect the pro forma growth of total revenue of the Q2 will be 72% to 78%, adjusting the revenue recognition of last-mile delivery services to net basis in Q2 of 2020 and 2021. We are excited with JDDJ’s strong growth momentum, and are confident that year-over-year growth rate of JDDJ’s revenue will be over 80% in Q2 and will further accelerate in the second half of 2021.”The Company also announces $150 million share repurchase plan.","news_type":1,"symbols_score_info":{"DADA":0.9}},"isVote":1,"tweetType":1,"viewCount":2176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":116442179,"gmtCreate":1622816965891,"gmtModify":1704191830690,"author":{"id":"3578224654391596","authorId":"3578224654391596","name":"keozmi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578224654391596","idStr":"3578224654391596"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/116442179","repostId":"1105681635","repostType":4,"repost":{"id":"1105681635","kind":"news","pubTimestamp":1622800841,"share":"https://ttm.financial/m/news/1105681635?lang=&edition=fundamental","pubTime":"2021-06-04 18:00","market":"us","language":"en","title":"3 Top Robinhood Stocks Wall Street Thinks Will Soar 25% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=1105681635","media":"Motley Fool","summary":"Analysts expect one of them to skyrocket a lot more than 25%.","content":"<p>Robinhood investors like quite a few stocks that aren't exactly favorites for analysts. If memes are floating on the internet about a given stock, there's a pretty good chance that it's popular on Robinhood but not so much on Wall Street.</p>\n<p>However, there are also several stocks that retail investors on the commission-free trading platform and analysts alike hold in high regard. Here are three top Robinhood stocks that Wall Street thinks will soar 25% or more.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0548d25733705cf21e71b0a7eaad8add\" tg-width=\"2000\" tg-height=\"1333\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Apple</b></p>\n<p>You might think that with a market cap topping $2 trillion, there's not much room for <b>Apple</b> (NASDAQ:AAPL) to grow. Analysts would disagree. The average one-year price target for the technology leader reflects a premium of nearly 28% over the current share price.</p>\n<p>Apple is the second-most widely held stock among Robinhood investors. Why? Probably because they realize the incredible moat and growth prospects that Apple enjoys with its iPhone-centric ecosystem.</p>\n<p>I think this ecosystem could expand enough for Apple to hit Wall Street's price target. The increased availability of high-speed 5G wireless networks continues to fuel demand for the newer iPhone models. Apple's services and wearables revenue also continues to grow significantly.</p>\n<p>Over the long run, my view is that technological innovations will keep Apple among the favorite stocks for both Robinhood investors and Wall Street analysts. Look for more augmented reality functionality on the way. There's also speculation that Apple could launch a foldable iPhone in 2023. A future market cap of $3 trillion or more isn't out of the question at all.</p>\n<p><b>Amazon.com</b></p>\n<p>Robinhood investors and analysts also agree on another so-called FAANG stock--<b>Amazon.com</b> (NASDAQ:AMZN). The internet giant ranks as the ninth most popular stock on Robinhood. Analysts think that Amazon's share price could rise 31% over the next 12 months.</p>\n<p>There are two key growth drivers that could enable Amazon to deliver that kind of growth. The company's Amazon Web Services (AWS) cloud platform continues to fire on all cylinders and is highly profitable. Amazon is also experiencing strong momentum with its digital advertising business.</p>\n<p>Value investor Bill Miller even thinks that these two units could account for most of Amazon's valuation within the next couple of years. He's also bullish about the company's business-to-business and logistics platforms. I suspect Miller's optimism is on point.</p>\n<p>Don't forget e-commerce, though. Amazon remains the biggest e-commerce company in the world. Online sales still account for less than 14% of total retail sales in the U.S. There's a lot of room for Amazon to run in its core business.</p>\n<p><b>Bionano Genomics</b></p>\n<p>You might be at least a little surprised by the third top Robinhood stock on our list that Wall Street really likes. The average price target for <b>Bionano Genomics</b> (NASDAQ:BNGO) is a whopping 80% higher than the stock's current price.</p>\n<p>Bionano reported better-than-expected Q1 results in May. Revenue jumped 179% year over year to a record-high $3.2 million. Although the company remained unprofitable, its bottom line moved in the right direction.</p>\n<p>Customers appear to like Bionano's Saphyr genome mapping system. As the install base grows, the company's recurring revenue from consumables grows. That's the kind of business model that investors hope could really pay off over the long run.</p>\n<p>Bionano projects that it will have 150 Saphyr systems in the field by the end of this year, up 50% from the end of 2020. The company also anticipates receiving accreditation for additional laboratory-developed tests for Saphyr soon. Bionano is riskier than Apple or Amazon, but analysts think it could be a huge winner over the near term.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Robinhood Stocks Wall Street Thinks Will Soar 25% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Robinhood Stocks Wall Street Thinks Will Soar 25% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-04 18:00 GMT+8 <a href=https://www.fool.com/investing/2021/06/04/3-top-robinhood-stocks-wall-street-thinks-will-soa/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Robinhood investors like quite a few stocks that aren't exactly favorites for analysts. If memes are floating on the internet about a given stock, there's a pretty good chance that it's popular on ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/04/3-top-robinhood-stocks-wall-street-thinks-will-soa/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","BNGO":"Bionano Genomics","AMZN":"亚马逊"},"source_url":"https://www.fool.com/investing/2021/06/04/3-top-robinhood-stocks-wall-street-thinks-will-soa/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105681635","content_text":"Robinhood investors like quite a few stocks that aren't exactly favorites for analysts. If memes are floating on the internet about a given stock, there's a pretty good chance that it's popular on Robinhood but not so much on Wall Street.\nHowever, there are also several stocks that retail investors on the commission-free trading platform and analysts alike hold in high regard. Here are three top Robinhood stocks that Wall Street thinks will soar 25% or more.\nIMAGE SOURCE: GETTY IMAGES.\nApple\nYou might think that with a market cap topping $2 trillion, there's not much room for Apple (NASDAQ:AAPL) to grow. Analysts would disagree. The average one-year price target for the technology leader reflects a premium of nearly 28% over the current share price.\nApple is the second-most widely held stock among Robinhood investors. Why? Probably because they realize the incredible moat and growth prospects that Apple enjoys with its iPhone-centric ecosystem.\nI think this ecosystem could expand enough for Apple to hit Wall Street's price target. The increased availability of high-speed 5G wireless networks continues to fuel demand for the newer iPhone models. Apple's services and wearables revenue also continues to grow significantly.\nOver the long run, my view is that technological innovations will keep Apple among the favorite stocks for both Robinhood investors and Wall Street analysts. Look for more augmented reality functionality on the way. There's also speculation that Apple could launch a foldable iPhone in 2023. A future market cap of $3 trillion or more isn't out of the question at all.\nAmazon.com\nRobinhood investors and analysts also agree on another so-called FAANG stock--Amazon.com (NASDAQ:AMZN). The internet giant ranks as the ninth most popular stock on Robinhood. Analysts think that Amazon's share price could rise 31% over the next 12 months.\nThere are two key growth drivers that could enable Amazon to deliver that kind of growth. The company's Amazon Web Services (AWS) cloud platform continues to fire on all cylinders and is highly profitable. Amazon is also experiencing strong momentum with its digital advertising business.\nValue investor Bill Miller even thinks that these two units could account for most of Amazon's valuation within the next couple of years. He's also bullish about the company's business-to-business and logistics platforms. I suspect Miller's optimism is on point.\nDon't forget e-commerce, though. Amazon remains the biggest e-commerce company in the world. Online sales still account for less than 14% of total retail sales in the U.S. There's a lot of room for Amazon to run in its core business.\nBionano Genomics\nYou might be at least a little surprised by the third top Robinhood stock on our list that Wall Street really likes. The average price target for Bionano Genomics (NASDAQ:BNGO) is a whopping 80% higher than the stock's current price.\nBionano reported better-than-expected Q1 results in May. Revenue jumped 179% year over year to a record-high $3.2 million. Although the company remained unprofitable, its bottom line moved in the right direction.\nCustomers appear to like Bionano's Saphyr genome mapping system. As the install base grows, the company's recurring revenue from consumables grows. That's the kind of business model that investors hope could really pay off over the long run.\nBionano projects that it will have 150 Saphyr systems in the field by the end of this year, up 50% from the end of 2020. The company also anticipates receiving accreditation for additional laboratory-developed tests for Saphyr soon. Bionano is riskier than Apple or Amazon, but analysts think it could be a huge winner over the near term.","news_type":1,"symbols_score_info":{"AAPL":0.9,"AMZN":0.9,"BNGO":0.9}},"isVote":1,"tweetType":1,"viewCount":2477,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}